Recent report by Miyachi et al. (32) showed improvement of ILD in patients with psoriasis through the use of secukinumab (anti-IL-17A monoclonal antibody), thus supporting IL-17A blockade as a potential treatment option for ILD. Here, IL17A is linked to psoriasis.